What is Survodutide?
Survodutide is a dual GLP-1 and glucagon receptor agonist being developed by Boehringer Ingelheim. It has shown remarkable results for both weight loss and non-alcoholic steatohepatitis (NASH/MASH), significantly reducing liver fat content while achieving substantial weight loss.
Key Benefits & Mechanisms
Significant weight loss (up to 19%)
Dramatic liver fat reduction
NASH/MASH improvement
Improved metabolic biomarkers
Dual pathway activation
Hepatoprotective effects
Cardiovascular risk reduction
Research Summary
Survodutide Phase II trials showed 18.7% weight loss and up to 87% reduction in liver fat in NASH patients. Particularly promising for the large unmet need in NASH/MASH treatment. Multiple Phase III trials ongoing for both obesity and liver disease.